` PBLA (Panbela Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

PBLA
vs
S&P 500

Over the past 12 months, PBLA has underperformed S&P 500, delivering a return of -100% compared to the S&P 500's +14% growth.

Stocks Performance
PBLA vs S&P 500

Loading
PBLA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PBLA vs S&P 500

Loading
PBLA
S&P 500
Difference
www.alphaspread.com

Performance By Year
PBLA vs S&P 500

Loading
PBLA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Panbela Therapeutics Inc vs Peers

S&P 500
PBLA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Panbela Therapeutics Inc
Glance View

Market Cap
1.5k USD
Industry
Biotechnology

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 4 full-time employees. The company went IPO on 2014-07-29. The firm is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The firm is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.

PBLA Intrinsic Value
Not Available
Back to Top